Skip to content
Governance Register

← US public companies

Rubius Therapeutics, Inc.

SEC CIK 1709401 · RUBY · last insider filing 2023-02-27

Directors (from insider filings)

NameCapacity as filedFilings
Cagnoni Pablo J Director · Chief Executive Officer filed 2018 - 2023
Schaffert Susanne Director filed 2022 - 2022
Afeyan Noubar Director filed 2018 - 2022
Epstein David R Director filed 2018 - 2022
Rosenblatt Michael Director filed 2018 - 2022
Cuss Francis M Director filed 2018 - 2022
Sohn Catherine A. Director filed 2018 - 2022
Holles Natalie C. Director filed 2019 - 2022
Symonds Jonathan Director filed 2018 - 2022
Prener Anne Director filed 2019 - 2022
Flagship Ventures Fund IV General Partner LLC Director filed 2018 - 2021
Langer Robert Director filed 2018 - 2019
Pomerantz Roger Director filed 2018 - 2018

Officers (from insider filings)

NameTitle as filedFilings
Appelhans Dannielle Chief Operating Officer filed 2021 - 2023
Turka Laurence A. Chief Scientific Officer filed 2020 - 2023
Carmona Jose Chief Financial Officer filed 2020 - 2022
Keson-Brookes Maiken CLO & Corp. Secretary filed 2019 - 2022
Coughlin Christina M. Chief Medical Officer filed 2020 - 2021
OH Andrew M. Chief Financial Officer filed 2018 - 2020
Carpenter Christopher L. Chief Medical Officer filed 2018 - 2019
Nissen Torben Straight President filed 2018 - 2019

About this record

From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.

Source: SEC Insider Transactions Data Sets (Forms 3/4/5), US Federal Government public domain.